8 hours ago
3
ARTICLE AD BOX
India’s pharmaceutical exports remained connected a maturation way successful the past fiscal twelvemonth contempt planetary headwinds, crossing $28 cardinal during April–February FY26, portion manufacture leaders said the assemblage is connected people to astir treble successful size to $130 cardinal by 2030.Speaking astatine the inaugural league of the ‘Chintan Shivir: Scaling Up Pharma Exports’ connected Saturday, K Raja Bhanu, manager wide of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), said pharma exports stood astatine $28.29 cardinal successful April–February FY26, marking a 5.6 per cent summation implicit the aforesaid play of FY25.“Despite planetary challenges, pharmaceutical exports person been among the fewer sectors to support maturation momentum.
Exports during April–February FY26 stood astatine $28.29 billion, reflecting a maturation of 5.6 per cent compared to the aforesaid play successful FY25, led by formulations, biologicals, vaccines and AYUSH products,” Bhanu said.Bhanu said the Indian pharmaceutical sector, presently valued astatine astir $60 billion, is projected to turn to $130 cardinal by 2030. He added that pharma exports reached $30.47 cardinal successful FY2024–25, signaling a 9.4 per cent year-on-year maturation contempt planetary pricing pressures and commercialized volatility.
He said Pharmexcil is targeting $65 cardinal successful exports by 2030, backed by argumentation prioritisation, diversification beyond accepted markets, higher FDI inflows and faster regulatory clearances.India presently ranks 3rd globally successful pharmaceutical accumulation by volume, with shipments reaching much than 200 markets, helium said. Bhanu besides noted that implicit 60 per cent of India’s pharma exports spell to highly regulated markets, highlighting the sector’s prime and compliance standards.According to him, the United States accounts for 34 per cent of India’s pharmaceutical exports, followed by Europe astatine 19 per cent.Commerce caput Rajesh Agrawal said the assemblage is apt to enactment connected a affirmative trajectory adjacent if export targets beryllium hard to conscionable successful dollar terms, fixed the weakening rupee.“The people we person acceptable appears hard to meet, but we volition stay connected a affirmative trajectory,” Agrawal said.He added that careless of whether targets are achieved successful dollar terms, export maturation would inactive bespeak positively successful rupee presumption arsenic the Indian currency continues to weaken against the US dollar.Pharmexcil president Namit Joshi said India is apt to extremity the existent fiscal twelvemonth astatine levels comparable to FY25, portion flagging the effect of front-loaded US buying.“That is wherefore we expect to extremity up adjacent to past year’s performance, with immoderate maturation coming from that,” Joshi said.Joshi said tariff-related issues successful 2025 led to higher procurement of medicines worthy $1.6 cardinal successful the US, supra mean levels, and that this is expected to power FY26 numbers.
US tariff backdrop whitethorn signifier aboriginal outlook
While the contiguous absorption remains connected export resilience, the outer environment—especially successful the US, India’s biggest pharma market—could go a cardinal adaptable going forward.The US has announced a caller tariff model targeting patented drugs and definite high-value pharmaceutical ingredients manufactured extracurricular America, with duties of up to 100 per cent acceptable to instrumentality effect betwixt August and September 2026 aft a modulation period.However, the near-term deed to India whitethorn beryllium constricted due to the fact that generic medicines are presently exempt, and astir 90 per cent of India’s pharmaceutical exports to the US are generics, arsenic per a GTRI report. The study said India exported $9.7 cardinal worthy of pharmaceuticals to the US successful 2025, accounting for 38 per cent of its planetary pharma exports of $25.8 billion.
